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Glossary of acronyms 63 
Ac Acylation 
  ACD Allergic Contact Dermatitis 
ADRA Amino Acid Derivative Reactivity Assay  
AOP Adverse Outcome Pathway 
ARE Antioxidant/electrophile response element 
BT Buehler test  
 
CD54 
Cluster of Differentiation 54, a co-stimulatory adhesion molecule that is expressed in 
dendritic cells 
CD86 
Cluster of Differentiation 86, a co-stimulatory adhesion molecule that is expressed in 
dendritic cells 
CV70 Concentration of test chemical yielding a cell viability of 70% in the U-SENS™ method 
DA Defined Approach 
 DC Dendritic cells 
 DIP Data interpretation procedure 
DPRA Direct Peptide Reactivity Assay  
DSA05 Dose per skin area that produced a positive response in 5% of the tested population 
EC1.5 
Lowest concentration inducing a 1.5-fold change in luciferase activity in the assays 
measuring KE2
 
EC150 
Effective concentrations yielding a relative fluorescence intensity [RFI] of 150% for CD86 in 
the h-CLAT test 
EC200 
Effective concentrations yielding a relative fluorescence intensity [RFI] of 200% for CD54 in 
the h-CLAT test 
EC3 
Effective concentration of a test chemical that gives a stimulation index with a three-fold 
increase over the vehicle control in the LLNA 
EC3 Concentration with 3 fold luciferase induction in the KeratinoSens
TM
 test 
GARD Genomic allergen rapid detection  
GPMT Guinea Pig Maximization test 
GST Glutathione S-transferase  
HAF Hazard assessment framework 
h-CLAT Human Cell Line Activation test  
HMT Human Maximization Test  
HRIPT Human Repeat Insult Patch Test 
hTCPA human T cell priming assay  
IATA Integrated approach to testing and assessment  
IC Induction concentration in GPMT 
IC50 Concentration for 50% reduction of viability in KeratinoSens
TM
 test 
IL-18 Interleukin-18 
 IL-8 Interleukin-8 
 IL-8 Luc  Interleukin-8 Reporter Gene Assay  
KE Key Event 
 KE1 Key event 1: Covalent interaction with skin proteins 
KE2 Key event 2: Events in keratinocytes 
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KE3 Key event 3: Events in dendritic cells 
KE4 Key event 4: Events in lymphocytes 
Keap1 Kelch-like ECH-associated protein 1  
LLNA Local Lymph Node Assay 
LOEL Lowest observed effect level 
Log Kow n-octanol/water partition coefficient 
MA Michael addition 
 MHC Major histo-compatibility complex  
MIE Molecular initiating event 
NOEL No Observed Effect Level  
NQ01 NADPH-quinone oxidoreductase 1  
Nrf2 Nuclear factor (erythroid-derived 2)-like 2  
OECD Organization for Economic Co-operation and Development 
QMM Quantitative Mechanistic Models  
(Q)SAR  (Quantitative) Structure-Activity Relationship 
RFI Relative fluorescence intensity  
SB Schiff base formation 
SI Stimulation index  
 SLS  Sodium lauryl sulfate  
SM Supplementary material 
SN1 Unimolecular nucleophilic substitution 
SN2 Bimolecular nucleophilic substitution 
SNAr Nucleophilic aromatic substitution 
STS Sequential Testing Strategy  
U-SENS™ U937 cell line activation Test  
 64 
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Abstract 74 
 75 
The assessment of skin sensitization has evolved over the past few years to include in vitro assessments 76 
of key events along the adverse outcome pathway and opportunistically capitalize on the strengths of in 77 
silico methods to support a weight of evidence assessment without conducting a test in animals. While 78 
in silico methods vary greatly in their purpose and format; there is a need to standardize the underlying 79 
principles on which such models are developed and to make transparent the implications for the 80 
uncertainty in the overall assessment. In this contribution, the relationship of skin sensitization relevant 81 
effects, mechanisms, and endpoints are built into a hazard assessment framework. Based on the 82 
relevance of the mechanisms and effects as well as the strengths and limitations of the experimental 83 
systems used to identify them, rules and principles are defined for deriving skin sensitization in silico 84 
assessments. Further, the assignments of reliability and confidence scores that reflect the overall 85 
strength of the assessment are discussed. This skin sensitization protocol supports the implementation 86 
and acceptance of in silico approaches for the prediction of skin sensitization. 87 
Keywords: In silico, in silico toxicology, computational toxicology, computational toxicology protocols, 88 
(Q)SAR, expert alerts, expert review, skin sensitization, defined approach, integrated approaches to 89 
testing and assessment (IATA), extractables and leachables. 90 
  91 
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1. Introduction 151 
Allergic contact dermatitis (ACD) is a common skin condition that results from the induction of a dermal 152 
immunological response after repeated exposure to a skin-sensitizing substance. ACD poses a significant 153 
public and occupational health concern, and much effort has been dedicated to the identification and 154 
classification of skin sensitizers. Historically, assessors have relied on human (Human repeat insult patch 155 
tests (HRIPT) and Human maximization tests (HMT)) or animal testing, the latter commonly using guinea 156 
pig (Guinea pig maximization (GPMT) and Buehler tests(BT))(Organisation for Economic Co-operation 157 
and Development (OECD), 1992) and mouse models (Local lymph node assay (LLNA))(OECD 2010a) to 158 
identify potential skin sensitizers. The guiding principles of the “3Rs” (replacement, reduction, and 159 
refinement) as applied to animal research(RUSSELL and BURCH 1959) have influenced the 160 
implementation of regulations, such as the 7th amendment of the Cosmetic Directive (Council Directive 161 
76/768/EEC of 1976-07-27; Cosmetics Regulation: REGULATION (EC) No. 1223/2009), European 162 
substances legislation No. 1907/2006 (Registration, Evaluation, Authorization and Restriction of 163 
Chemicals (REACH)) in the European Union; and Section 4(h) (Reduction of Testing in Vertebrates) of the 164 
Toxic Substances Control Act (TSCA) in the United States. These regulations either prohibit the use of 165 
animal testing or only allow animal testing if results obtained by alternative methods are not sufficient 166 
to assess the sensitizing potential of a chemical. The “3Rs” together with the need for higher throughput 167 
and more mechanistically informative methods, continue to drive the development of non-animal 168 
methods. In this regard, in silico, in chemico, and in vitro methods in concert play an integral role in the 169 
hazard assessment of skin sensitization. 170 
In silico models, along with in vitro tests, have been and continue to be developed for predicting the 171 
outcome of the four key events (KEs) described in the OECD adverse outcome pathway (AOP) for skin 172 
sensitization (OECD 2014). It is generally accepted that the skin sensitizing hazard of a chemical can be 173 
effectively assessed through the integration of non-animal approaches (Kleinstreuer et al., 2018; OECD, 174 
2017). However, there may be data gaps that are generated through the exclusion of chemicals that do 175 
not meet the physicochemical property requirements for the in vitro tests, and in silico methods that 176 
could be used to fill such gaps may lack transparency as they are sometimes viewed as “black box” tools. 177 
There is also no consensus on how to integrate in vitro data and/or in silico predictions for these events 178 
with existing in vivo data.  179 
The protocol detailed in this publication outlines a framework in which in silico methods could be 180 
applied and integrated with existing in vivo and in vitro experimental data to identify potential skin 181 
9 
 
sensitizers, and to provide consensus on the development of models and the interpretation of model 182 
results. In silico methods are likely to play an important role in understanding the hazard and risk 183 
associated with chemicals (Myatt et al. 2018). Assessing sensitization is a necessary component of 184 
classification and labelling, workers’ safety and occupational health (where ~20-30% of compounds may 185 
be sensitizers), regulation of cosmetics and other industrial chemicals as well as product discovery. 186 
Previous studies have evaluated the potential use of in silico tools to predict sensitization hazard or 187 
potential (Roberts and Aptula 2014; Roberts, Aptula, and Patlewicz 2006). However, there remains a 188 
need for in silico guidelines and the definition of principles and procedures that are specific to the 189 
prediction of skin sensitization relevant mechanisms. To this end, this skin sensitization protocol has 190 
been developed based on the experience of a cross-industry consortium comprising 39 different 191 
organizations and represents a consensus of how to use in silico methods to predict skin sensitization. 192 
1.1 Hazard Assessment Framework (HAF) 193 
Figure 1 provides a representation of a generic hazard assessment framework. The hazard assessment 194 
framework defines the relationship between mechanisms and effects that are relevant for the 195 
prediction of skin sensitization. The mechanisms and effects are molecular perturbations and 196 
manifestations, respectively, that lead to the adverse outcome and are reflected in the AOP for skin 197 
sensitization (Myatt et al. 2018). The mechanisms and effects are assessed based on in silico or existing 198 
experimental data. Each mechanism/effect assessment is assigned a reliability score which reflects the 199 
inherent quality of the assessment (Section 4). The relevance (scientific predictivity) of the 200 
effect/mechanism is also assessed. Rules and principles are used to combine the mechanisms/effects to 201 
derive an assessment of non-apical endpoints (i.e., endpoint 1 and 2 in figure 1) that are relevant for 202 
sensitization. The non-apical endpoint assessment is assigned a confidence score, which is a reflection of 203 
the reliability, relevance, and completeness of the assessment. Non-apical endpoints are combined via 204 
rules and principles to derive an overall assessment for skin sensitization (the apical endpoint) with an 205 
associated confidence score. The framework is designed to derive an assessment for hazard, with risk 206 
being outside the scope of the protocol.  Figure 2 shows the hazard assessment framework for 207 
sensitization and the relationships between the following endpoints: 208 
• Covalent interaction with skin proteins 209 
• Events in keratinocytes 210 
• Events in dendritic cells 211 
• Skin sensitization in vitro (defined approach) 212 
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• Skin sensitization in rodent lymphocytes 213 
• Skin sensitization in rodents 214 
• Skin sensitization in humans (weight of evidence) 215 
A comprehensive and mechanistic assessment for skin sensitization includes the four KEs described in 216 
the AOP as well as available in vivo data and other supporting elements (OECD 2014). A mechanistic 217 
understanding of the sensitizing process is detailed within the AOP for skin sensitization and becomes 218 
necessary in the development of this framework. In order for a chemical to exert a sensitizing effect, a 219 
series of well-defined stages/events occur that lead to the development of effector T cells (as opposed 220 
to regulatory T cells, which lead to tolerance(OECD 2014). A chemical’s ability to induce each KE is 221 
critical information that is used in the development of the HAF. Sensitization is acquired through two 222 
distinct phases. During the initial induction phase, the immune system is primed through dendritic cell 223 
presentation of the sensitizing chemical to naïve T-cells. The induction phase occurs upon first contact 224 
with the sensitizer and a physiological response is typically mild or absent. Upon re-exposure to the 225 
same sensitizer, the primed immune system is activated and an inflammatory response occurs. This 226 
phase is called the elicitation or challenge phase and results in the manifestation of the symptoms 227 
associated with ACD: the appearance of rashes, blisters, and welts. A comprehensive assessment of the 228 
skin sensitization potential of a chemical includes the four KEs that are described in the induction phase 229 
(OECD 2014). 230 
1.1.1 Key Event (KE) 1: Molecular Initiating Event (MIE) – covalent interaction with skin 231 
proteins 232 
The MIE for acquiring skin sensitization is the covalent binding of an electrophilic chemical to a 233 
nucleophilic protein, typically the thiol group of cysteine or the primary amine group of lysine (Figure 3). 234 
The interaction of the sensitizer (hapten) with the protein leads to the formation of a stable hapten-235 
protein conjugate. While a hapten-bound protein may result from direct interaction of the protein with 236 
an electrophile, some chemicals require either metabolic (pro-haptens), or abiotic transformation 237 
through oxidation (pre-haptens) prior to complexing with dermal proteins. The hapten-protein 238 
interaction depends on the number of available nucleophilic target residues, steric considerations 239 
(targets on the surface of a protein are more easily accessible than those in folds), and the 240 
microenvironment (hydrophilic or hydrophobic)(OECD 2014). The formation of this complex is critical for 241 
the activation of the immunological cells that are responsible for sensitization.  242 
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1.1.2  Key Event (KE) 2: Events in keratinocytes 243 
It is accepted that interactions with the hapten lead to the modulation of inflammation-related 244 
pathways and oxidative stress response pathways in keratinocytes (OECD 2014)(Figure 3).  245 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor that trans-locates into the 246 
nucleus of keratinocytes and binds to antioxidant/electrophile response elements (ARE). This in turn, 247 
initiates the transcription of genes related to oxidative stress responses, such as NADPH-quinone 248 
oxidoreductase 1 (NQ01) and glutathione S-transferase (GST). Nrf2 is repressed and controlled by the  249 
Kelch-like ECH-associated protein 1 (Keap1), which facilitates the ubiquitination and degradation of 250 
Nrf2. Keap1 is a cysteine (thiol) rich protein which can be modified by electrophiles (haptens) and 251 
oxidants. This modification to Keap1 induces conformational changes in the protein that releases bound 252 
Nrf2, allowing it to bind AREs and promote the expression of cyto-protective mechanisms (OECD, 2012). 253 
In addition, interaction of the hapten with keratinocytes stimulates the production of pro-inflammatory 254 
cytokines such as IL-18 (Natsch 2010). The release of cytokines by keratinocytes (among other factors) 255 
plays a role in stimulating the maturation of dendritic cells (Sumpter, Balmert, and Kaplan 2019) 256 
1.1.3  Key Event 3: Events in dendritic cells 257 
Langerhans cells and dermal DCs are responsible for the presentation of the protein-hapten complex to 258 
naïve T-cells in the lymph node during the induction phase (Figure 3). Following the uptake of the 259 
protein-hapten conjugate, DCs process and present these peptide fragments in the context of major 260 
histocompatibity complex (MHC) molecules to naïve T cells. Matured DCs migrate to the dermis and to 261 
the lymph node under the influence of cytokines and chemokines that are secreted by keratinocytes and 262 
fibroblast in the dermis (OECD 2014; Sumpter et al. 2019). During maturation, cell surface markers, 263 
adhesion molecules, cytokines, and chemokines are upregulated. The upregulation of co-stimulatory 264 
adhesion molecules (e.g., CD54, CD86) ensures that professional antigen presenting cells develop and 265 
initiate an immune response. When there is a lack of co-stimulation, T-cell anergy (a state in which the 266 
lymphocytes remain hypo-responsive after encounter with antigen) and a lack of sensitization may 267 
result (OECD 2014; Vocanson et al. 2009) 268 
1.1.4  Key Event 4: Events in lymphocytes 269 
Presentation of the fragmented peptide complex within the MHC to naïve T-cells results in their 270 
activation. This leads to the differentiation and proliferation of memory T-cells. Memory T-cells migrate 271 
to the dermis and also circulate throughout the body. Upon re-exposure to the same hapten, the 272 
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memory T-cells are activated (elicitation phase) and the immune response is triggered; the result is the 273 
manifestation of ACD, an irreversible immunologic response (OECD 2014).  274 
KE 1-4 can be used to assess the ‘skin sensitization in vitro endpoint’, which in turn can be extrapolated 275 
to the ‘skin sensitization in humans’ endpoint as shown in Figure 2. These in vitro endpoints can also be 276 
predicted by in silico models as outlined in the HAF (Figure 2) and described in Section 2.  277 
The availability of in vivo (usually rodent) data is relevant to the overall assessment of ‘skin sensitization 278 
in humans’ and facilitates the development of in silico methods to predict the results. KE 4 (lymphocyte 279 
activation and proliferation) can be measured with an in vivo mouse model and the adverse outcome 280 
(e.g., erythema) can be assessed in guinea pigs. The events in lymphocytes (when assessed in mice) and 281 
the guinea pig assessments can be combined to provide an overall assessment of ‘Skin sensitization in 282 
rodents’. Skin irritation may be a confounding factor and so is also considered at this point. An overall 283 
assessment of ‘skin sensitization in humans’ can be determined through the integration of the ‘skin 284 
sensitization in vitro’ and ‘skin sensitization in rodents’ endpoints. Historical human test data may also 285 
be available and in silico models can be developed to facilitate its prediction. This information also 286 
propagates into the ‘skin sensitization in humans’ endpoint.  287 
The HAF consists of evaluation of KE1-4 via in vitro or in vivo testing, physio-chemical properties, and 288 
human data (Figure 2). The assumption is made that all chemicals are capable of dermal penetration as 289 
a conservative measure (Fitzpatrick, Roberts, and Patlewicz 2017). The endpoints in the framework may 290 
be informed through available data, in silico predictions, or data acquired through conducting a test. The 291 
protocol defines general rules and principles for integrating data towards an overall prediction of the 292 
adverse outcome in humans. The incorporation of lines of evidence that may not directly relate to 293 
sensitization; such as skin irritation, means that the protocol takes the form of an integrated approach 294 
to testing and assessment (IATA).  295 
1.2  Integrated approach to testing and assessment (IATA) 296 
Given the definition of an AOP for skin sensitization and the availability of historical data, the endpoint is 297 
effectively predicted using an IATA. Limited data for the KEs along the AOP have restricted the 298 
development and applicability of in silico models to predict these endpoints while in vitro testing is 299 
mainly used to derive an assessment of the activation of KEs along the AOP pathways. This may change 300 
in the future, as more data become available and more robust in silico models can be developed.  301 
Nonetheless, through an integrated scheme, the overall endpoint of ‘skin sensitization in humans’ is 302 
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assessed as a function of the activity at each KE, with additional evidence from either existing data or in 303 
silico predictions of in vivo responses and metabolic biotransformation. Previous research has focused 304 
on developing such schemes and these non-animal integrated strategies are receiving interest from 305 
regulatory authorities. The publication of the ‘Interim Science Policy: Use of Alternative Approaches for 306 
Skin Sensitization as a Replacement for Laboratory Animal Testing’ is an example of regulators adopting 307 
this more integrated approach(EPA 2018). Additional non-animal assessment strategies are currently 308 
being developed and validated, and more approaches may be adopted for regulatory purposes in the 309 
future (Kleinstreuer et al. 2018). While several integrated approaches invoke the AOP and integrate the 310 
KEs to derive an overall assessment of skin sensitization, it has been argued that failure or ability to 311 
sensitize could be explained by (in)sufficient activity in the ‘covalent interaction with skin proteins’ 312 
endpoint, and the evaluation of subsequent KEs is less important (Roberts and Aptula 2008). To this end, 313 
the authors believe that a HAF that can facilitate multiple approaches is necessary. The ideal framework 314 
should be generic enough to facilitate possible variations in analysis while maintaining a high level of 315 
reproducibility and transparency. Rules and principles for combining results for each endpoint are 316 
defined in this protocol. These rules will set the foundation for the reproducibility and flexibility of the 317 
framework presented here.  318 
1.3 Defined Approaches           319 
  320 
Previous approaches have incorporated rules that connect various aspects of the toxicological pathway 321 
to skin sensitization. The “2 out of 3” integrated testing strategy approach to skin sensitization hazard 322 
identification proposed by BASF uses a data interpretation procedure (DIP) that labels a chemical as a 323 
sensitizer or non-sensitizer based on the concordant reactivity of the chemical in two in vitro tests for 324 
KE1 - KE3 (Urbisch et al. 2015). Several other integrated strategies have been developed to assess either 325 
hazard or potency (Section 1 of the supplementary materials and described in detail elsewhere (OECD 326 
2017)). Each approach addresses particular elements of the AOP. At the time of this manuscript, no 327 
single approach is viewed as being superior to the others and selected approaches vary based on the 328 
availability of computational tools and data. 329 
1. In silico methodologies and models 330 
Historically, in silico models have focused on the prediction of animal data (particularly the LLNA), and 331 
few have considered the rest of the mechanisms established in the AOP. Therefore, it is necessary to 332 
examine how in silico tools could be developed to model mechanisms related to the KEs described 333 
earlier.  334 
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Depending on the availability of high-quantity data, different types of in silico models can be developed. 335 
Table 1 provides a list of data sources. Larger amounts of data, preferably with a strong mechanistic 336 
understanding of a specific toxicological process, can support many different types of models. Datasets 337 
that cover a broad chemical space can support the development of global Quantitative Structure-338 
Activity Relationship ((Q)SAR) models, provided that the descriptors are relevant and mechanistically-339 
related to the endpoint that is being predicted (Roberts et al. 2007). Where data are sparse, generated 340 
with different protocols, or generated through multiple mechanistic pathways (as may be the case in 341 
human studies), methods such as expert-alerts or read-across may be more appropriate. 1 Statistical 342 
models may also be developed; however, these models are potentially limited by a smaller applicability 343 
domain. On the other hand, the mechanistic understanding and classification of chemicals into a 344 
mechanistic domain means that local QSAR modeling may be a feasible approach for assessing events 345 
related to the sensitizing endpoint. One of the earliest attempts to develop a local mechanism-based 346 
QSAR model to predict EC3 concentrations in the LLNA, used the Relative Alkylation Index (RAI, a 347 
function of electrophilic reactivity, lipophilicity, and dose)(Roberts et al. 1991; Roberts and Williams 348 
1982). Subsequently, several Quantitative Mechanistic Models (QMM) have been developed with the 349 
goal of identifying physicochemical and other descriptors that contribute to a mechanistic 350 
understanding of an endpoint of interest (Aptula and Roberts 2006; Roberts and Aptula 2014; Roberts, 351 
Aptula, and Patlewicz 2011; Roberts and Natsch 2009). The rest of Section 2 discusses the mechanisms 352 
or effects that could be predicted and which types of in silico methodologies could facilitate the 353 
predictions. On a general note, in silico methods typically derive structure activity relationships (SAR) for 354 
organic salts by using the structure of the freebase. In cases where a metallic fragment will be removed 355 
in the generation of the freebase to derive the SAR form of the structure, the potential hazard posed by 356 
the metal should be considered. In the area of skin sensitization, removing nickel fragments may lead to 357 
an underestimation of hazard for structures that contain them.  To more accurately facilitate predictions 358 
in these cases, the metal may be attached to the ligand, or the metal may be kept unattached in the 359 
training set. The model builder may also decide to remove the salt structure entirely from the training 360 
set; thereby, excluding the metal from the applicability domain of the model. 361 
The following sections describe general considerations for building in silico models based on the 362 
available chemistry, biology, and testing data. Section 1 of the supplementary material provides a 363 
detailed description of the experimental data that are relevant for assessing skin sensitization. Methods 364 
                                                          
1
 The reader is referred to (Myatt et al., 2018) for a more general discussion on these methods 
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to assess the reliability of the data as well as in silico predictions have been previously described by 365 
(Myatt et al. 2018) and are summarized in Section 2 of the supplemental material.  366 
2.1 Covalent interaction with skin proteins, KE1 367 
In silico and or experimental assessments for whether a given compound will participate in covalent 368 
interactions with skin proteins are primarily generated based on understanding of metabolism, reaction 369 
domain assignment and protein reactivity. 370 
2.1.1 Dermal Metabolism 371 
The allergenic potential of a chemical may be increased or decreased through metabolic pathways or 372 
abiotic oxidation; these factors are important for predicting a chemical’s potential to induce dermal 373 
sensitization. Metabolic detoxification takes place in two phases, which may or may not occur 374 
simultaneously. Phase II metabolism appears to be more abundant and active in the skin than in the 375 
liver, although Phase I enzymes – though not dominant – are inducible in the skin (Dumont et al. 2015). 376 
Given differences in expression profiles between the liver and skin, the potential use of liver metabolic 377 
data to predict metabolites in the skin will necessitate strategies for accounting for the differences in 378 
the expression of isoenzymes between liver and skin (Madden et al. 2017).
2
 One strategy for predicting 379 
metabolic activation towards sensitization in dermal tissues is to derive alerts to indicate if a chemical 380 
may be a pro-hapten. This approach is currently limited by the size of the databases of pro-haptens and 381 
a general lack of skin specific data (although knowledge has been gained through experience over the 382 
years). Currently, it appears that the range of structural features that are activated towards sensitization 383 
via metabolic pathways is small. Given the absence of skin-specific metabolic data, it is challenging to 384 
definitively conclude on the topic. (Natsch and Haupt 2013) investigated the activation of pro-haptens 385 
by rat liver S9 fractions in the KeratinoSens
TM
 assay, and identified phenolic and alkoxy groups attached 386 
to a benzene ring, some aromatic amines, and conjugated dienes in or in conjunction with six-387 
membered ring as structural features that may require pro-activation to behave as haptens in the assay 388 
(Natsch & Haupt, 2013; Bergström, et al., 2006; Bergström, et al., 2006). The features identified do not 389 
represent a comprehensive and thoroughly defined list of features that undergo metabolic 390 
transformation leading to sensitization. 391 
                                                          
2
 The supplemental material provides a brief summary of the differences between skin and liver 
metabolic enzymes with relevance to humans 
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2.1.2 Reaction Domain 392 
Existing mechanistic information on hapten-protein interactions has been used to construct in silico 393 
models for predicting sensitization potential based on a compound’s structure and known – or predicted 394 
– reaction chemistry. The mechanisms for forming protein-hapten complexes involve the interaction 395 
between an electrophilic chemical (hapten) and the nucleophilic moiety on a skin protein (generally thiol 396 
or primary amine groups). Common mechanisms by which the sensitizer (hapten) may bind to the 397 
protein are: Michael addition, acylation, Schiff base formation, unimolecular nucleophilic substitution 398 
(SN1), bimolecular nucleophilic substitution (SN2), or nucleophilic aromatic substitution (SNAr). Within 399 
each of these mechanistic domains, there are mechanistic alerts and structural alerts. Structural alerts 400 
are defined as molecular substructures that can activate the toxicological effect or mechanism (Myatt et 401 
al. 2018). Structural alerts that are characterized by a common reaction site are defined as mechanistic 402 
alerts (Aptula and Roberts 2006; Enoch, Madden, and Cronin 2008; Roberts et al. 2015). Structural and 403 
mechanistic data do not always suggest a toxic effect, however – some structural features, such as steric 404 
hinderance, have been found to mitigate toxicity by decreasing the ability of the hapten to covalently 405 
bind to proteins – and these features may improve an in silico model by providing this additional 406 
information.  407 
Classification of mechanistic and structural alerts within mechanistic domains allows for local QSAR 408 
modelling within each domain (OECD 2011), provided that one has the relevant quantitative information 409 
describing the protein-hapten bond. To this end, the following physical-chemical property descriptors 410 
are commonly used to predict interactions between haptens and proteins: Molecular weight (MW), Log 411 
P, solubility, rotational bonds, electronic and topological descriptors (e.g., quantum mechanics 412 
calculations), or chemical structure-based descriptors (e.g., the presence or absence of different 413 
functional groups) (OECD 2011). The factors constituting an acceptable and validated model have been 414 
described in previous work (Myatt et al. 2018). However, it must be noted that due to the expert nature 415 
of deriving structural alerts based on reaction chemistry, existing in silico tools can only incorporate our 416 
current knowledge of protein-hapten reaction chemistry (rather than the quantification of a physical or 417 
biological process), and that future models could be improved as we increase our mechanistic 418 
understanding of these processes.  QSARs on the other hand, are not limited by current knowledge of 419 
mechanistic processes and the combined use of structural alerts and QSARs may add value to the 420 
analysis.  421 
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2.1.3 Protein Reactivity 422 
Protein reactivity has been studied using model nucleophiles to assess protein-chemical interaction in in 423 
chemico assays. While the binding mechanism between the protein and the chemical could be described 424 
based on reaction chemistry as discussed in the previous section, any in silico tools (either statistical or 425 
expert rule-based) developed based on in chemico assay data will be limited in their ability to predict 426 
sensitization due to pro-activation. To overcome this limitation, predictions based on reaction 427 
chemistry, protein reactivity, and dermal metabolism should be considered in concert to generate an 428 
overall assessment (described in Section 3.1).  429 
While protein reactivity measurement is feasible across all reaction domains described in section 2.1.2, 430 
experimental results show that within the domain of Schiff base formers there is a lower correlation 431 
between the in chemico-based DPRA model and in vivo and human data (Urbisch et al. 2015). While 432 
Schiff base formation may be theoretically feasible, the abundance of water within the peptide 433 
reactivity testing environment may limit some reactions. As such, peptide reactivity was found to 434 
correlate poorly with the potency of aldehydes, as Schiff base formation may be limited under testing 435 
conditions in the DPRA (Natsch et al. 2015). Further analysis revealed that more potent Schiff base 436 
formers (atranol, chloratranol, and salicylaldehyde) are reactive under physiological conditions (Natsch 437 
et al. 2012). However, the LLNA EC3 values of Schiff base formers are well correlated (R
2
 = 0.95) with a 438 
combination of logP and a reactivity parameter based on substituent constants (Roberts et al. 2006). 439 
Differential reactivity within a mechanistic domain is an issue that could become relevant in the 440 
development of in silico models, and particularly in those that use read-across. Such instances may not 441 
be unique to the protein reactivity mechanism but may require examination across all toxicological 442 
endpoints.  443 
2.2 Events in keratinocytes, KE2 444 
A comprehensive prediction of keratinocyte activation covers events on several levels of biological 445 
organization and includes the expression of biochemical, genomic, and proteomic pathways, and 446 
quantifies the release of pro-inflammatory mediators that stimulate dendritic cells in KE3 (OECD 2014). 447 
Validated protocols are established for assessing the induction of ARE dependent pathways, and, as 448 
such, the development of in silico models can be considered for this assessment. However, the breadth 449 
of information and data describing other pathways could be informative and may drive the development 450 
of in silico models to predict additional pathways in the future.  451 
18 
 
Statistical modelling is feasible; however, the availability of data is a critical factor influencing the 452 
success of measures to implement models based on AOP in vitro tests.  Descriptors relating to the 453 
covalent modification of the cysteine-rich Keap1 protein could be used to develop mechanistically-454 
relevant QSAR models.  There may be limitations in predicting compounds which preferentially bind 455 
hard nucleophiles such as lysine since the in vitro tests predicting KE2 rely on the cysteine-dependent 456 
modification of Keap1. Therefore, false negative predictions may be more common for compounds that 457 
react via acyl transfer, within the domain of Schiff base formers, including short chain aldehydes, and 458 
longer chain saturated alkanals. Other electrophiles that prefer hard nucleophiles may also produce 459 
false negative predictions (Urbisch et al. 2015). This could be a potential issue in read-across analysis 460 
and should be addressed during an expert review.  461 
In silico prediction of KeratinoSens
TM
 and LuSens (in vitro test methods for assessing ARE activation in 462 
keratinocytes) data yields dichotomous (either positive or negative) test results (OECD 2018b). However, 463 
integrated assessments of potency may require continuous data input such as EC1.5 (the lowest 464 
concentration inducing a 1.5-fold change in luciferase activity), IC50 (concentration for 50% reduction of 465 
viability) and EC3 values (concentration with 3 fold luciferase induction) (Natsch et al. 2015). 466 
2.3 Events in dendritic cells, KE3 467 
Dendritic cell activation is similar to keratinocyte activation in that predictions can be made on the levels 468 
of protein and gene expression. Methods have been validated for measuring the expression of specific 469 
cell surface markers which contribute to T cell activation and proliferation. Published databases may 470 
contain data for dendritic cell gene expression of co-stimulatory and adhesion molecules (cell surface 471 
markers: CD54 and CD86) and Interleukin-8 (IL-8) (Nukada et al. 2011; Urbisch et al. 2015).  472 
As noted for the KE2 endpoint, care must be taken when integrating testing data from the various in 473 
vitro assays into KE3 in silico models due to differences in the types of data that may be produced by 474 
different assays. The continuous data outcomes predicted for these assays, such as the EC150 and EC200 475 
values from the h-CLAT assay; the CV70 and the EC150 in the U-SENS™ assay could be used in integrated 476 
strategies to predict potency. These and other in silico predictions of the Ind-IL8LA (induced interleukin-477 
8 luciferase activity) could be used to support the hazard assessment; however, since a statistically-478 
derived experimental variable (confidence interval) is needed to determine a positive call, a more 479 
practical approach may be to dichotomize the assay results and make binary predictions.  480 
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Often, it is helpful to build models that use threshold values to convert continuous data into 481 
dichotomous (yes or no) values. For any of the in vitro or in chemico test methods that are used to 482 
assess a KE along the AOP, using threshold values, in silico predictions could generate dichotomous 483 
predictions of KE activity using these in vitro or in chemico test endpoints.  484 
2.4 Events in human lymphocytes, KE4 485 
The lack of standardized data makes in silico predictions of in vitro T cell activation and proliferation 486 
challenging. A paucity of data for this endpoint is not surprising, however, as the value of predicting this 487 
key event remains in question, and the significance of an in vitro estimate of KE4 can only be speculated 488 
at this time. It is possible that the magnitude of the T cell responses at KE4 may be the key event that 489 
allows us to make distinctions between different potency classes in vitro (OECD 2014), but the issue has 490 
not been settled. Consequently, only the in vivo Local Lymph Node Assay has been accepted as a 491 
standardized method for assessing this endpoint.  492 
2.5 Events in rodent lymphocytes, KE4 493 
The LLNA is the only standardized in vivo method used to measure the proliferation of lymphocytes in 494 
response to immune system priming by a test chemical as well as the potency of the chemical as a skin 495 
sensitizer. The results of the assay are reported as the concentration of the chemical needed to induce 496 
T-cell proliferation by a pre-chosen factor (usually 3, 1.6, or 1.8 times the baseline amount as assessed 497 
by the stimulation index (SI))(OECD 2010b, 2010a, 2018a). The LLNA has been used extensively, and it is 498 
quite feasible to build in silico models using statistical and rule-based methods due to the ready 499 
availability of data, although, the majority of such data is proprietary. While the publicly-available LLNA 500 
data could facilitate statistical modeling, the model coverage may be reduced for industrial applications. 501 
However, the combined use of statistical modeling and structural alert definitions could be a strategy to 502 
overcome this limitation. 503 
The irritation potential of a chemical could be a confounding factor in the experimental LLNA, and the 504 
issue of irritation translates into in silico assessments. Training set examples and analogs under 505 
consideration for read-across should be examined for their irritation potential. Studies indicate that non-506 
sensitizing irritants (such as surfactants) could be overestimated by the LLNA, leading to false positive 507 
results (Ball et al. 2011; OECD 2010a). While this is certainly the case for sodium lauryl sulfate (SLS), 508 
chloroform/methanol, Triton X-100, oxalic acid, methyl salicylate, and nonanoic acid, analysis of 509 
chemicals known to be skin irritants has not validated this generalization across the entire class of non-510 
sensitizing irritants(Ball et al. 2011). Most non-sensitizing irritants are negative in the LLNA and those 511 
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that are positive may produce borderline results (with few exceptions). For example, the sensitization 512 
hazard of SLS  is derived from a clear dose-response curve that is indicative of a positive LLNA result; 513 
however, when a weight-of-evidence (WoE) approach is used, the interpretation of the LLNA results may 514 
be reversed. There is no evidence that SLS is a skin sensitizer in humans despite exposure; albeit limited, 515 
it lacks a structural alert for sensitization and is a strong irritant (Basketter et al. 2009). Hence, Basketter 516 
et al. 2009 have suggested that for the SI results obtained for SLS in the LLNA (SISLS), a WoE approach 517 
could be developed around the false positive result to implement this approach in a general sense. 518 
Using SLS as reference for a test chemical with unknown skin sensitization hazard, irritant potential and 519 
SI predictions (SItest); if the SItest< SISLS and no structural alert exists of sensitization, then the LLNA 520 
prediction could be a suspected false positive and confidence in a positive prediction of the “skin 521 
sensitization in humans” endpoint is low. The reverse may also be considered: If SItest> SISLS and an 522 
alerting structure exists for sensitization; then the chemical may be suspected to be a true positive 523 
(Basketter et al. 2009). The confidence could be adjusted accordingly based on the weight of evidence 524 
presented. This sort of analysis would be considered with a low reliability LLNA study which may have 525 
been conducted at irritant concentrations. Generally, the LLNA test is preceded by dose finding range 526 
studies and minimally irritating to not irritating concentrations are tested. 527 
Some LLNA protocols (LLNA-DA, and LLNA-BrdU-ELISA) use non-radioactive methods to quantify 528 
lymphocyte proliferation. Results from these protocols could be combined in training sets that would 529 
facilitate binary level predictions; however, varying criteria for predicting a positive call may complicate 530 
the prediction of a meaningful continuous SI or ECX value (where x is 3, 1.6, or 1.8 depending on the 531 
LLNA protocol used) from such a dataset and would require a valid strategy for integrating the data. 532 
Another relevant issue with LLNA datasets that arises in the curation process is the comparison and 533 
combination of SI and EC3 values for tests conducted in different vehicles. While it seems logical that 534 
vehicle effects are normalized in the derivation of the SI and EC3 values, there are mechanisms that 535 
could lead to enhanced bioavailability depending on the choice of vehicle. The rapid evaporation of 536 
acetone, for example, may result in volatilization of the test chemical and decreased bioavailability; 537 
whereas dimethyl sulfoxide (DMSO) could potentially enhance penetration. Differing results may be 538 
obtained between two LLNA tests using different vehicles and this could influence hazard assessment 539 
(Hoffmann 2015). In some cases, vehicle effects may lead to the assignment of a chemical to two 540 
neighboring potency classes (Anderson, Siegel, and Meade 2011; Basketter, Gerberick, and Kimber 2001; 541 
Dumont et al. 2016; Hoffmann 2015). This inherent variability in the LLNA data (not exclusively caused 542 
by different vehicles) is translated to in silico predictions. When combining multiple data sources, the 543 
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most conservative SI and ECx values could be adopted, unless there is compelling evidence that the 544 
vehicle is potentiating or attenuating the effect of the test chemical. A less conservative, but valid, 545 
approach is to use the mean, or median values, among other valid approaches (Hoffmann et al. 2018).  546 
2.6 Skin sensitization in rodents 547 
The skin sensitization in rodent endpoint is evaluated through the use of the GPMT and the BT method. 548 
Guinea pigs were historically used to assess skin sensitization. Similar to the LLNA, while public data are 549 
available, much of the GPMT and BT data are proprietary. The data that exists could facilitate statistical 550 
modeling, the derivation of expert alerts, and read-across.  551 
2.7      Skin sensitization in humans 552 
Historical data exist for this endpoint and, based on data quantity, expert-alert derivation and read-553 
across may be preferable to statistical methods. In silico predictions could be useful for the prediction of 554 
dichotomized results of positive/negative. Potency predictions could be challenging based on data 555 
availability. Evidence to support human predictions includes clinical data (DPT) and usage/occupational 556 
exposure data (Api et al. 2017). Further, the integration of the ‘skin sensitization in vitro’ and the ‘skin 557 
sensitization in rodents’ endpoints, along with any direct human evidence, are considered together as 558 
weight of evidence for the prediction of the ‘skin sensitization in humans’ endpoint. 559 
3.  Endpoint assessment and confidence 560 
The protocol details the integration of data with different reliabilities and relevance. Further, there may 561 
be cases in which information that is critical to an assessment is missing. This section outlines the 562 
rules/principles that could be applied when deriving an assessment and its associated confidence based 563 
on the totality of evidence presented.  Figure 4 shows the hazard assessment framework annotated with 564 
references to where each of the following sections applies. 565 
3.1         Covalent interaction with skin proteins assessment  566 
Assessment of the ‘covalent interaction with skin proteins’ endpoint includes consideration of metabolic 567 
transformation, reaction chemistry, and DPRA/ADRA predictions. Figure 5 shows how rules could be 568 
made around the available information to derive an overall prediction of hazard. If an experimental 569 
result is positive for the methods assessing KE1 (DPRA/ADRA), then a positive assessment of the 570 
‘covalent interaction with skin proteins’ is warranted. However, the reliability of the prediction, as 571 
assessed by the scheme presented in Table 6 of the supplementary material and described in (Myatt et 572 
al. 2018), varies depending on the quality of the information presented and this has an influence on the 573 
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confidence score. The quality and reliability of an in silico DPRA/ADRA prediction could be assessed 574 
according to the expert review criteria described in (Myatt et al. 2018). Additional considerations for 575 
both experimental (test article) and in silico (training set examples and analogues) results include 576 
situations in which DPRA/ADRA could lead to a false positive result due to oxidizing properties of the 577 
test chemical, which can lead to peptide dimerization. An expert review could inform on whether or not 578 
this is likely and if the assessment and confidence score need adjustment. Assessments of negative 579 
DPRA/ADRA results vary based on consideration of the metabolic potential of the chemical together 580 
with knowledge of reaction chemistry. In general, when the chemical is expected to be out of the 581 
metabolic domain of the DPRA/ADRA then precedence is given to clearly-defined knowledge of reaction 582 
chemistry (including mitigating factors, such as sterics) in the overall assessment of the ‘covalent 583 
interaction with skin proteins’ endpoint. If the reaction chemistry indicates a mechanism leading to 584 
sensitization; particularly if the mechanism requires pro-activation then the overall assessment of the 585 
‘covalent interaction with skin proteins’ is positive based on reaction chemistry knowledge, but the 586 
confidence is medium. If the test article is out of the metabolic domain, negative in DPRA/ADRA and no 587 
mechanistic alert could be identified in the structure of the test chemical based on reaction chemistry, 588 
then the DPRA/ADRA result is inconclusive as it cannot be said that the overall assessment is either 589 
negative or positive. However, if metabolism is not predicted to occur and the chemical is considered 590 
within the metabolic domain of the DPRA/ADRA, then the negative result should be given consideration 591 
in the overall assessment. A negative DPRA/ADRA prediction (within the DPRA/ADRA metabolic domain) 592 
and a positive mechanistic alert lead to a negative overall assessment, with a medium confidence level, 593 
given that the DPRA/ADRA result is experimental and the positive mechanistic alert introduces some 594 
uncertainty.  An expert review would consider whether or not the test chemical is within the Schiff base 595 
reaction domain. In these cases a negative DPRA/ADRA result may be mechanistically justifiable due to 596 
the protein-hapten interaction being unfavorable under the test conditions as a result of the abundance 597 
of water; particularly for chemicals that are indicated as less potent sensitizers by other methods. In this 598 
case, the overall assessment could be considered positive (after expert review) with a low confidence. 599 
This positive result is based on giving greater precedence to the mechanistic alert within this domain, 600 
and the decreased relevance of the DPRA/ADRA due to the differential reactivity of chemicals within the 601 
Schiff base domain. Further, co-elution of the test article with the model nucleophile may lead to false 602 
negative predictions, although this occurs to a lesser extent in the ADRA than in the DPRA (Fujita et al. 603 
2019). 604 
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In cases where the DPRA/ADRA result is positive, but no mechanistic alert can be assigned, it is worth 605 
considering whether mechanistic knowledge could be provided by the protein reactivity results 606 
particularly when close analogs point to the same structure-activity relationship. Figure 5 shows the 607 
‘covalent interaction with skin proteins’ endpoint and the confidence score decision tree based on RS1 608 
data. The confidence scores are expected to vary based on reliability and relevance; as such, there are 609 
several possible permutations of the decision tree. These general “rules” are expanded to provide a 610 
sense of the confidence assigned to assessments with varying reliabilities and relevance, Supplementary 611 
Material, section 4 (SM 4).  612 
 613 
3.2 Events in keratinocytes 614 
The confidence score obtained for the activation of the events in keratinocytes towards skin 615 
sensitization varies based on the Log Kow of the chemical. If there is a positive prediction (RS1, 616 
experimental) and the Log Kow is <5, then the result is assigned a high confidence. If the Log Kow is 617 
greater than 5, then the confidence is medium for a positive result and low for a negative prediction, 618 
since limited information is available for such chemicals (OECD 2018b). Regardless of Log Kow values, 619 
negative results could be further assessed based on the occurrence of metabolism and the chemical 620 
mechanism of action.  621 
A metabolic alert (indicative of an expected metabolic transformation) along with a negative RS1/2 622 
experimental or RS3 in silico result, could indicate reduced relevance of the in vitro assays predicting KE2 623 
in this case – possibly because limited metabolic competency of the cells used in the assay are 624 
responsible for a false negative. Therefore, the overall assessment would be negative but with a low 625 
confidence score. If there is no biochemical transformation predicted, then the chemical mechanism of 626 
action could be considered. A negative assessment for a chemical within the acyl transfer domain and 627 
Schiff Base domain is conservatively assigned a low confidence score based on the preference of 628 
chemicals within these domains for the lysine instead of the cysteine moiety (representing decreased 629 
relevance). It is worth mentioning that some chemicals within these domains are accurately predicted as 630 
true negatives and a review of the relevance is necessary to assign a higher confidence. Such a review 631 
might include an examination of close analogs (or the test structure if data is available) for their 632 
assessment in the DPRA/ADRA and or an animal model. If close analogs are positive in the DPRA/ADRA 633 
and the lysine moiety; but not cysteine, is implicated for covalent modification then the relevance of the 634 
KE2 assays for predicting the test structure may be challenged. However, if cysteine modification is 635 
apparent in the DPRA/ADRA (positive for covalent interaction with skin proteins), it is more difficult to 636 
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challenge the relevance of the KE2 assays on that basis and conflicting information is presented by the 637 
two KEs. The analogs may be further assessed and screened for existing animal data and/or in silico 638 
predictions of the LLNA or GPMT. This serves the purpose to assess the likelihood of a false negative 639 
prediction of the test structure by the KE2 assays. Where a false negative seems likely, the low 640 
confidence is appropriate. In cases where the analogs are true negatives, the confidence score could be 641 
increased to a medium level and this reflects that while uncertainty is somewhat reduced, there is not 642 
absolute certainty in the assessment.  Within any other domain, a negative KE2 prediction is considered 643 
with high confidence, given RS1/2 data. Varying reliabilities of the data could change the confidence 644 
scores in figures 6A and B (see SM Table 9). 645 
3.3 Events in dendritic cells 646 
An overall assessment of the events in dendritic cells could be made based on the h-CLAT (Figure 7), U-647 
SENS™ or IL-8 Luc assays (Figure 8). A positive response from these assays typically translates to a 648 
positive overall call for the events in dendritic cells with high confidence in the activation of the 649 
dendritic cells towards sensitization, but an expert reviewer would be needed to adjust overall calls and 650 
confidence scores for certain chemical classes, structural features, and physical-chemical properties. For 651 
example: some chemical classes, such as surfactants, may lead to false positive results in the U-SENS™, 652 
and a negative result for a chemical that has a Log Kow greater than 3.5 is considered inconclusive for the 653 
h-CLAT. The pro/pre-hapten status of the test chemical is also relevant in each of the three assays. 654 
Negative results for structures in which a site of metabolism leading to sensitization has been identified 655 
are accepted with a medium level confidence from the h-CLAT, U-SENS™ and IL-8 assays. In cases where 656 
there are no additional parameters confounding the prediction, then the confidence level is high for the 657 
negative predictions from the h-CLAT, U-SENS™, and IL-8 Luc assays.  658 
3.4 Skin sensitization in vitro 659 
Integrating data to derive an overall assessment for the ‘skin sensitization in vitro’ endpoint that 660 
correlates with the in vivo endpoint is an active area of research. A number of defined approaches (DA) 661 
which use varying DIPs have been developed to determine an overall assessment of skin sensitization 662 
using non-animal/in-vitro/in silico models. Any of the DAs described in Section 1 may be adopted here. 663 
There has been regulatory acceptance of the “AOP 2 out of 3” approach and the KE3/1 sequential 664 
testing strategy (STS) as alternatives to the LLNA for regulatory submission to the United States 665 
Environmental Protection Agency (US EPA) (EPA 2018). Here, we discuss how to derive an overall 666 
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assessment and confidence when the “AOP 2 out of 3” approach is used within the framework 667 
presented in this protocol.   668 
The “AOP 2 out of 3” uses the outcome of three individual assays that map to three KEs to derive a final 669 
assessment; however, within the framework presented the assay results are integrated and propagated 670 
to the three endpoints related to each key event. The difference between the “AOP 2 out of 3” and the 671 
approach used in the framework is subtle, but is worth mention. The “AOP 2 out of 3” approach 672 
considers the outcome of the experimental systems – DPRA, KeratinoSens
TM
, and h-CLAT – but within 673 
the framework presented, the: ‘Covalent interaction with skin proteins’, ‘Events in keratinocytes’, and 674 
‘Events in dendritic cells’ (KEs in the AOP) are considered. These KEs are assessed based on knowledge 675 
of reaction chemistry and mechanistic understanding that is not explicitly considered within the “AOP 2 676 
out of 3” approach. Similar to the “AOP 2 out of 3,” an overall assessment of hazard for the ‘skin 677 
sensitization in vitro’ endpoint is determined based on a 2 out of 3 consensus among the endpoints. If 678 
outcomes (in silico/experimental) are available for only two endpoints, and they have aligned outcomes, 679 
the overall assessment of the endpoint is based on the concordant assessments and the lower 680 
confidence score propagates. The adoption of the lower confidence score reflects a conservative view of 681 
the assessment at this stage of the analysis. However, if the confidence scores have the same value for 682 
non-concordant assessments, then the overall prediction for the ‘skin sensitization in vitro’ endpoint is 683 
inconclusive. Where there are two concordant assessments, and the non-concordant assessment occurs 684 
with high confidence, then the overall confidence could be lowered by one level. Table 2 provides 685 
examples showing the derivation of the overall assessment and the rationale for the final confidence 686 
score. An alternative point of view suggests that the assays that predict the ‘events in keratinocytes’, 687 
and ‘events in dendritic cells’, are dependent on the ability of the test chemical to bind protein and 688 
therefore point to the activation of the molecular initiating event, ‘covalent interaction with skin 689 
proteins’.  In this point of view, any improvement in predictive performance that results from 690 
integrating the KEs across the AOP is a result of reducing the influence of technical limitations of each of 691 
the assays (Roberts 2018; Roberts and Patlewicz 2018).  692 
 693 
 694 
 695 
 696 
 697 
 698 
 699 
 700 
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 701 
 702 
The discussion thus far has focused on assessing hazard from in vitro data, but there are also existing 703 
strategies for predicting potency in humans from in vitro data based on the DAs described in Section 1 704 
and reviewed in (Kleinstreuer et al. 2018). The Artificial Neural Network Model for Predicting LLNA EC3 705 
(Shiseido); Bayesian Network DIP (BN-ITS-3) for Hazard and Potency Identification of Skin Sensitizers 706 
(P&G); Sequential Testing Strategy (STS) for Sensitizing Potency Classification Based on in Chemico and 707 
In Vitro Data (Kao); and ITS for Sensitizing Potency Classification Based on In Silico; In Chemico, and In 708 
Vitro Data (Kao) were found to predict potency class equally well, or better than the LLNA. Similar to the 709 
earlier discussion on hazard, the DAs for assessing potency use biological assay outcomes 710 
(mechanisms/effects assessment within the HAF e.g. DPRA, KeratinoSens
TM
, h-CLAT) as endpoints and 711 
may integrate the information with in silico methods to determine a potency class. Within the HAF 712 
presented, the assay outcomes (in vitro/in silico effects/mechanisms assessment) are interpreted in the 713 
context of their toxicological significance and integrated to determine a toxicological endpoint according 714 
to the rules and principles outlined in previous sections. The overall assessments of the KE endpoints 715 
may substitute for the outcome of the individual test methods in data interpretation procedures.  716 
3.5 Skin sensitization in vitro to skin sensitization in human extrapolation 717 
Extrapolation of in vitro skin sensitization results to human skin sensitization predictions is necessary to 718 
satisfy the European Union’s 7
th
 Amendment of the Cosmetic Directive and REACH regulations which 719 
require and prefer the use of non-animal test methods for assessing the human skin sensitization 720 
endpoint. The definition of the AOP and the mechanistic information provided by the assays that map to 721 
the AOP allow the human hazard identified for the ‘skin sensitization in vitro’ outcome to be propagated 722 
to the human endpoint. The relevance of the integrated in vitro battery of tests is equally weighted with 723 
the in vivo studies except in unique cases; for example, when metabolism is thought to influence the 724 
outcome. As such, no change in confidence (reliability and relevance of the prediction) is expected due 725 
to the extrapolation of in vitro hazard. 726 
3.6 Skin sensitization in rodent lymphocytes 727 
A negative result in the LLNA is propagated to the skin sensitization in rodent lymphocytes endpoint 728 
with high confidence. A weak sensitizer may require investigation of the skin irritation potential of the 729 
chemical, particularly if the result is derived from a lower-reliability study that may not have considered 730 
irritation prior to designing the test. The skin irritation potential will be determined through a HAF that 731 
will be published in a separate protocol. Positive results due to confounding factors from irritants usually 732 
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result in a low-level increase in lymphocytes which could be misinterpreted as a weak sensitizing 733 
response. In cases where a chemical is found to have a strong skin irritation potential and is a weak 734 
sensitizer and the influence of irritation cannot be ruled out, a positive assessment with low confidence 735 
could be assigned to the ‘Events in rodent lymphocytes’ endpoint (Figure 9).  736 
3.7 Skin sensitization in rodents 737 
This endpoint integrates guinea pig (GPMT and BT) and mouse (LLNA) data. In the absence of LLNA data, 738 
the endpoint could be determined through the scheme shown in Figure 10. If guinea pig tests are not 739 
conducted according to standard protocols, irritation could become a confounding factor in the 740 
interpretation of the guinea pig test results and influence the relevance of the study (OECD 1992).  741 
Freund’s complete adjuvant (FCA) is used to maximize the guinea pig response; however, FCA may also 742 
lower the irritation threshold. The implication is that concentrations that were identified as non-743 
irritating and suitable for the challenge reaction might in fact produce an irritant response. Further, a 744 
hyperirritable state may be induced by the test article during the induction phase that is not 745 
represented in the control, unless a suitably irritating surrogate is used to induce the hyperirritable state 746 
in the controls (Kligman and Basketter 1995; OECD 1992). An irritant effect cannot be distinguished from 747 
an allergic response by visual examination. As such, post challenge examination is helpful in 748 
distinguishing a sensitization response from an irritant effect. Chemicals that are identified as irritants 749 
could be confidently predicted as non-sensitizers if observations of erythema dissipate within one day of 750 
challenge and/or there is a negative re-challenge test one week after the initial challenge (Kligman and 751 
Basketter 1995). A positive result for a chemical that is irritating but predicted to be a weak sensitizer is 752 
afforded a low confidence score if deviations from OECD 1996 result in decreased reliability and 753 
relevance of the study as discussed above.  754 
 755 
When both guinea pig and mouse data are available and are concordant, then the result is translated to 756 
the ‘skin sensitization in rodent’ endpoint with exact or higher confidence scores being adopted. For 757 
example, if the LLNA is positive with medium confidence and the GPMT/BT is positive with low 758 
confidence, then the skin sensitization in rodent endpoint is assessed as positive with medium 759 
confidence. In cases where the data are discordant, the strategy for deriving an overall assessment may 760 
vary case-to-case. A high reliability guinea pig test has an advantage over the LLNA because it includes 761 
both induction and challenge phases, and is as such, more representative of the entire sensitization 762 
process. However, in contrast to the LLNA, the guinea pig test results are based on a qualitative measure 763 
and a subjective endpoint. Potency is better assessed through the LLNA since it is derived from dose-764 
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response relationships and the read-out is quantitative; nonetheless, some chemical classes are over-765 
classified in the LLNA. It is valuable to consider how the challenge reaction affects interpretation of an 766 
assessment. It could be argued that the LLNA is an assay and non-specific reactions can occur that may 767 
or may not relate to allergenic potential (respiratory sensitizers test positive in the LLNA, for example) 768 
while the dermal challenge in the guinea pig tests lends more confidence that any observations of 769 
sensitization are specific to the skin. A default principle that could be adopted is to evaluate the ‘skin 770 
sensitization in rodent’ endpoint based on either the LLNA or GPMT/BT assessment with the higher 771 
confidence score and conservatively decrease the score by one level to reflect any uncertainty. For 772 
example, an LLNA that is assessed as positive with medium confidence, and a GP test that is negative 773 
with low confidence, would lead to a ‘skin sensitization in rodent’ assessment as positive with low 774 
confidence. In these circumstances, a review of the predictions is prudent and the assessment and 775 
confidence scores may be adjusted based on the review.  776 
3.8 Skin sensitization in rodents to skin sensitization in human extrapolation  777 
There are two schools of thought on rodent-to-human extrapolation that draw from a two different 778 
perspectives on risk assessment: one is that LLNA potency categories and EC3 values correlate well with 779 
human potency categories and NOEL values, and could therefore be used as a surrogate for the NOEL 780 
and for direct prediction of human potency class (Basketter et al. 2005). Alternatively, a safety factor 781 
may be incorporated based on the interspecies variation that may occur between the mouse and 782 
humans; although, this factor could be lowered in cases where a better correlation may be expected 783 
(e.g., based on existing human data for a close analogue) (Roberts and Api 2018). Roberts and Api 2018, 784 
have defined alerts for cases where the LLNA is not a good predictor of human potency. Guinea pig tests 785 
also provide relevant information on hazard and potency. However, tests that use adjuvant and 786 
intradermal routes of exposure (GPMT) present a challenge for interpreting human potency, and in 787 
those situations potency estimation via the BT may be more relevant. The data however, could serve in 788 
a weight-of-evidence case for potency determination through interpretation and comparison of 789 
different test results and also with known benchmark chemicals (Kimber et al. 2001).  790 
3.9 Skin sensitization in humans 791 
The ‘skin sensitization in humans’ endpoint could be evaluated through several other endpoints such as 792 
the ‘skin sensitization in vitro’ endpoint (section 3.5), the ‘skin sensitization in rodent endpoints’ (section 793 
3.8), or through the integration of the ‘skin sensitization in vitro’, ‘skin sensitization in rodents’, and 794 
human assessments, combined with supporting data from non-standard endpoints such as photoallergy. 795 
29 
 
A positive HMT/HRIPT is indicative of adverse outcome in humans and can potentially be used to assign 796 
a potency class. In the absence of reliable studies, other sources of evidence may be sought. The first 797 
line of evidence arises from the toxicological relationships that could be drawn from the chemical’s 798 
structure. The presence of a structural alert for sensitization in humans provides evidence for the 799 
elicitation of the adverse outcome. Structural alerts and diagnostic patch testing with positive incidences 800 
in greater than 1% of the population (considered to be high incidence) in relation to low usage volume 801 
(a measure of exposure) provides evidence for the skin sensitization potential of a chemical, although it 802 
does not provide a definite assessment (Api et al. 2017). If a compound has no structural alerts and 803 
diagnostic patch testing data indicate < 1% frequency, the overall evidence may together indicate a 804 
negative assessment, especially if the use volume is high. It is important to note that the indication of a 805 
1% incidence rate is based on expert opinion and as such is not meant to represent a rule that requires 806 
strict compliance. Many combinations of scenarios are possible.  807 
In cases where human and in vitro/in vivo sensitization assessments do not align, additional information 808 
could be gathered from the ‘skin sensitization in vitro’ and/or ‘skin sensitization in rodents’ endpoints to 809 
build a weight of evidence case. There are many permutations of assay results at this level but some 810 
general guidance can be provided to the evaluator towards an overall assessment. It is generally 811 
recommended that the assessments that are assigned more frequently should be propagated to the 812 
overall human endpoint. However, if reliable human data (RS1/2) is available, then the assessment of 813 
this data is given priority in the decision-making process. Table 13 of the supplementary material 814 
expands on the principles to derive an overall assessment given in vitro and rodent evidence. Due to 815 
ethical concerns, human testing is no longer considered appropriate for most compounds, so much of 816 
the human data is older, or based on clinical reports, and may therefore lack information to assess its 817 
quality, necessitating the filter of expert opinion. Careful consideration is required in assessing 818 
confidence of the HMT and HRIPTs. For the HMT and, especially for the HRIPT as used by the fragrance 819 
industry, low doses are often tested as the goal is to corroborate an animal study while trying to avoid 820 
sensitizing the subjects. Therefore, there can be quite a bit of uncertainty in a negative result because a 821 
higher test concentration could potentially produce a positive result in humans.  822 
Table 3 shows factors to consider in assigning confidence to a human study in general. There are 823 
however some specific exceptions to these criteria when assessing the HMT and HRIPTs. The exposure 824 
scenarios in the HMT and HRIPT may not represent real-world exposure because the test chemical is 825 
applied under occlusive conditions and the outcomes can be viewed as subjective because an observer 826 
grades the skin reaction. 827 
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 828 
4. Case Studies 829 
The case studies demonstrate the interpretation of results when a series of statistical models ((Q)SARs), 830 
structural alerts, or read-across are used to fill data gaps for effects and mechanisms that are included in 831 
the hazard assessment framework. The studies demonstrate how aspects of the rules and principles are 832 
implemented to derive an assessment, reliability score and confidence score, when the assessment is 833 
made using either or both existing experimental data or in silico methods. 834 
4.1. Case 1a: Compound with conflicting data (“Skin Sensitization in vitro” endpoint 835 
determination) 836 
An assessor needed to determine the hazard associated with a compound. The compound was 837 
predicted to be reactive towards proteins via an Acyl or SN2 reaction, and could be assigned to a 838 
reaction domain based on reaction chemistry alerts.  Data that was generated based on OECD TG 442C 839 
(DPRA) was available for the compound. The data indicated that the compound was negative for protein 840 
reactivity. Based on adherence to the test guideline, a reliability score of RS1 was assigned to the study. 841 
In silico tools (statistical results (QSAR) and alerts) were available for the DPRA prediction, and these 842 
predictions were also negative. The statistical model and the alerts both had a reliability score of RS5.  In 843 
silico assessments of dermal metabolism were negative after an expert review. The review increased the 844 
reliability of the dermal metabolism alert from RS5 to RS3.  The overall assessment for ‘covalent 845 
interaction with skin proteins’ was negative; however, the confidence was assigned as medium, based 846 
on the conflicting mechanistic/reaction chemistry alert for protein reactivity, Figure 11a.  847 
 848 
There is experimental data for the KeratinoSens
TM
 assay which is afforded a positive assessment with a 849 
reliability score of RS1 (the study adhered to OECD TG 442D), so the overall assessment for the ‘Events 850 
in Keratinocytes’ KE is positive with high confidence. Experimental data is not available for the ‘Events in 851 
Dendritic Cells’ KE. The assessor would like to use the “2 out of 3” approach and is faced with two 852 
conflicting assessments based on in vitro data.  A statistical model (QSAR) was used to predict the results 853 
of the h-CLAT assay and the assessment is negative with a reliability score of RS3, after an expert review. 854 
The overall assessment of the ‘Events in Dendritic Cells’ KE is negative with a medium confidence. Based 855 
on the two concordant assessments with aligned confidence scores (Negative, Medium confidence), and 856 
a third assessment that is conflicting with high confidence (Positive, High confidence), the overall 857 
assessment of in vitro skin sensitization endpoint is negative with low confidence.   858 
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4.2 Case 1b: Compound with conflicting data (‘Skin Sensitization in Humans’ endpoint 859 
determination) 860 
A further assessment was completed for the same compound as in Case 1a. This assessor has LLNA and 861 
GPMT data with conflicting assessments. The LLNA data is positive with an EC3 (%) value that indicates 862 
weak sensitization. The study is assigned the lowest reliability score of 5 based on significant deviations 863 
from OECD Test No. 429 that could alter both the reliability and relevance of the study. In silico 864 
assessments using expert alerts and statistical models are both negative. The weak sensitizing effect and 865 
the mis-aligned in silico results prompt the assessor to consider the irritation potential of the chemical. 866 
Experimental data is available for the in vitro skin irritation test using the Reconstructed Human 867 
Epidermis (RHE) test method. The assessment of skin irritation is positive with a score of RS1. The 868 
assessor conducts an expert review of the LLNA and suspects a false positive LLNA result. The ‘Events in 869 
Rodent Lymphocytes’ endpoint could be assigned as positive with low confidence; however, the 870 
negative in silico results are more reliable and relevant in this situation and the negative assessment 871 
carries over to the ‘Events in Rodent Lymphocytes’ endpoint with medium confidence. The GPMT data is 872 
negative with a reliability of RS1 since the study adhered to OECD 406 and the irritant effect was 873 
considered in the study design and interpretation of results. In silico models agree with the experimental 874 
GPMT result. The overall assessment of ‘Skin sensitization in rodents’ is negative with a high confidence, 875 
Figure 11b.  876 
To further investigate the outcome in humans, the assessor conducted an in silico assessment using a 877 
set of  alerts that were developed using HMT and HRIPT data as a reference database and no alerting 878 
structure were found. No human study data were available; however, DPT data were available and 879 
consecutive patients showed frequencies of 0% in a study. The absence of positive DPT results are 880 
indicative of no sensitization in humans, although a conclusion cannot be made from DPT data alone.  881 
 882 
Given the weight of evidence presented in Case 1a and 1b a final determination of the ‘skin sensitization 883 
in humans’ can be made. In this case, a well conducted GPMT carried significant weight towards the 884 
negative sensitization assessment with high confidence; reflecting the high reliability and relevance of 885 
the information. Other evidence supporting a negative assessment included a negative protein binding 886 
test which was reinforced by negative in silico models predictions of protein binding; and negative 887 
(Q)SARs predicting the ‘Events in dendritic cells’, and LLNA.  The conflicting piece of information 888 
presented by the LLNA study was viewed as less reliable and relevant information due primarily to 889 
confounding irritant effects in the study. A second piece of conflicting information was presented by the 890 
KeratinoSens
TM
 experimental study.  While no specific explanation for this false positive was 891 
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determined, the body of negative evidence for the ‘skin sensitization in vitro’ endpoint supports the 892 
negative assessment and the low confidence reflects any uncertainty in the assessment of that 893 
endpoint. However, the ‘sensitization in vitro’ assessment does not discredit the ‘skin sensitization in 894 
rodents’ assessment. Since the in vitro and rodent endpoints are both equally relevant when the in vitro 895 
endpoint is derived through a defined approach, the endpoint that contains more reliable information 896 
contributes more to the overall confidence. The in vitro endpoint does not introduce any uncertainty in 897 
the GPMT experimental findings, and taken together with the DPT data, the final confidence score is 898 
high in this negative case, Figure 11c.  There may be instances where a higher level of conservatism is 899 
necessary than presented. In such instances, the confidence score could be reduced to medium, 900 
although a change in the assessment might be difficult to justify.  901 
4.3 Case 2a: Pro/pre-hapten assessment 902 
Figure 12a details the assessment for the mechanisms/effects that were considered in the case. A 903 
chemical is being screened for possible use in the cosmetics industry. It is expected to undergo 904 
metabolic transformation leading to the formation of quinones, which have a high probability to react 905 
via Michael addition (MA). There are positive alerts for dermal metabolism and the site of metabolism 906 
coincides with a pro-MA reactivity alert. Negative DPRA data are available and the DPRA study is 907 
assigned a reliability score of 1 based on adherence to OECD TG 442C. However, based on knowledge 908 
that the compound contains a pro-reactive feature that coincides with a site of metabolism, the 909 
relevance of the DPRA for testing the compound is challenged since any activity that results from a 910 
metabolic transformation may be missed. The DPRA test is considered not relevant for the compound 911 
tested, and the assessment of the ‘Covalent interaction with skin proteins’ is based on the assignment of 912 
a pro-reactive domain. Although there may be cases where a pro-reactive domain assignment does not 913 
lead to protein interaction due to deactivating features, a conservative approach to assessing the 914 
endpoint given a pro-reactive feature is to assign a positive assessment with a lowered confidence. No 915 
other in vitro data are available for the compound. A (Q)SAR was developed based on proprietary data 916 
for the KeratinoSens
TM
 assay. The test compound is assessed as positive in the (Q)SAR, with the pro-MA 917 
feature identified as significant by the model. After a review of the (Q)SAR prediction, the ‘Events in 918 
Keratinocytes’ is assessed as positive with medium confidence. No data or models were available for the 919 
‘Events in dendritic cells’ endpoint. Given the positive assessment for ‘Covalent interaction with skin 920 
proteins’ and the ‘Events in Keratinocytes’, the overall assessment for the ‘Skin Sensitization in vitro’ 921 
endpoint is made using the “2 out of 3” approach. The overall assessment of the ‘Skin Sensitization in 922 
vitro’ endpoint is positive with low confidence based on the two aligned positive assessments and the 923 
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lower confidence score propagating to the endpoint, Figure 12a. It is possible to extrapolate the existing 924 
hazard information to the ‘Skin sensitization in humans’ endpoint and assess it as positive with low 925 
confidence. 926 
4.4 Case 2b: Pro/pre-hapten assessment Example 2 927 
Consider an extension of the case presented in Section 6.3.   LLNA data are not available for the test 928 
compound but are available for close analogs. In addition there is a low quality guinea pig test for the 929 
test compound that indicates a positive sensitization response.  Read-across is performed using the 930 
LLNA data for the analogs. The analogs all contained the pro-reactive feature and formed a congeneric 931 
series that allowed interpolation of the LLNA EC3 value. The EC3 value was predicted to be 3.2%, 932 
indicative of a moderate sensitizer. The ‘Events in rodent lymphocytes’ endpoint was assessed as 933 
positive with medium confidence based on the read-across result. The guinea pig test is assigned a 934 
reliability score of RS5 based on deviations from OECD 406. A review of the study showed that for an 935 
induction concentration of 1%, the sensitization incidence is 100% suggesting that the compound could 936 
be classified as a Category 1A sensitizer. After an expert review of the study, the reliability score is 937 
increased to RS3. The overall assessment of the ‘Skin Sensitization in Rodents’ endpoint is assessed as 938 
positive, with medium confidence based on the weight of evidence presented by the LLNA read-across 939 
and guinea pig study.  940 
The ‘Skin sensitization in rodents’ and the ‘Skin sensitization in vitro’ endpoints both support that 941 
assignment of a positive hazard for the ‘skin sensitization in humans’ with medium confidence. Figure 942 
12b shows the flow of information within the hazard assessment framework.  943 
5. Reporting 944 
An important consideration towards in silico standardization, reproducibility and transparency is a 945 
consistent reporting format (Myatt et al. 2018). The general protocol (Myatt et al. 2018) describes a 946 
proposed reporting format that includes the elements that provide completeness of information. The 947 
report format is reproduced in Table 4 with a minor modification for the skin sensitization endpoint. In 948 
addition to the description of models, databases, and tools that were used, it is also recommended to 949 
describe any IATAs, DIPs or DAs that were used in deriving the overall assessment. The details that are 950 
suggested should allow another expert to repeat the process and achieve the same results. Further, the 951 
standardized report enables streamlined and consistent review of regulatory submissions across 952 
industries and endpoints. Section 5 of the  Supplementary Material (SM5) provides an example of a 953 
report for sensitization hazard. 954 
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6. Conclusion 955 
The skin sensitization in silico protocol presented here is the first publication to outline a systematic 956 
assessment of skin sensitization based on both experimental data and in silico predictions. It includes a 957 
HAF and provides general rules for the in silico toxicological assessment of chemicals within the 958 
framework. The framework is transparent and flexible as it does not require the generation of all 959 
endpoints to derive an overall assessment of ‘skin sensitization in humans’ and can accommodate 960 
quantitative and qualitative predictions and/or experimental results. There are cases where 961 
extrapolation to the human endpoint is possible and this has been described. The corresponding 962 
assessment of the confidence for all endpoints allows the protocol to be used in a variety of use cases. 963 
For example, assessments with low confidence scores may still have practical usage in screening or 964 
prioritization use cases. In addition, the protocol highlights experimental approaches or in silico models 965 
that could be incorporated into the HAF in the near future. Expert review is a critical element in any such 966 
procedure and items to consider as part of this review are listed to support a more consistent 967 
assessment. The standardization of the HAF for performing in silico methods is designed to support 968 
increased use and acceptance of in silico tools among regulatory agencies and industries alike. 969 
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sensitization. In silico models could be developed for any effect or mechanism within grey boxes.  996 
 997 
Figure 3. Adverse Outcome Pathway (AOP) for skin sensitization. MIE- molecular initiating event, KE (1-4) 998 
- Key Events 1-4. 999 
Figure 4. The hazard assessment framework annotated with sections that discuss the assessment and 1000 
confidence score of each endpoint. 1001 
 1002 
Figure 5. Decision tree showing how an overall assessment and confidence score could be derived for 1003 
the covalent interaction of skin proteins. The confidence scores are based on RS1 experimental data: 1004 
assuming relevant data and high reliability, and, in practice, confidence scores may need to be adjusted 1005 
based on reliability scores, SM Table 8. *If a pro-reactivity domain is assigned and the metabolic site 1006 
(determined using structural alerts for skin metabolism) coincides with the pro-reactivity domain center 1007 
then the reversal in assessment occurs. If the metabolic site and the reactivity domain center do not 1008 
align then the assessment is inconclusive. 
§
§The inconclusive result is applicable in situations where 1009 
structural alerts could be used to determine if a structure is expected to undergo metabolism but not 1010 
identify the metabolites. In this case, since the reactivity of the metabolite cannot be confirmed, a 1011 
conclusion cannot be made on the assessment. If the reactivity of the metabolites could be predicted 1012 
then the final assessment depends on the metabolite reactivity. 1013 
36 
 
Figures 6A. Decision trees showing how an overall assessment and confidence score could be derived for 1014 
the ‘events in keratinocytes’. The confidence scores here are based on RS1 experimental data: assuming 1015 
relevant data and high reliability, and, in practice, confidence scores may need to be adjusted based on 1016 
reliability scores. 1017 
 1018 
Figures 6B. Decision trees showing how an overall assessment and confidence score could be derived for 1019 
the ‘events in keratinocytes’. The confidence scores here are based on RS1 experimental data: assuming 1020 
relevant data and high reliability, and, in practice, confidence scores may need to be adjusted based on 1021 
reliability scores. 1022 
 1023 
Figure 7. Decision tree showing how an overall assessment and confidence score could be derived for 1024 
the ‘events in dendritic cells’ based on the h-CLAT assay. The confidence scores here are based on RS1 1025 
experimental data: assuming relevant data and high reliability, and, in practice, confidence scores may 1026 
need to be adjusted based on reliability scores. 1027 
 1028 
Figure 8. Decision tree showing how an overall assessment and confidence score could be derived for 1029 
the ‘events in dendritic cells’ based on the U-SENS™ and IL-8 Luc assay data. The confidence scores here 1030 
are based on RS1 experimental data: assuming relevant data and high reliability, and, in practice, 1031 
confidence scores may need to be adjusted based on reliability scores, SM Table 10. 1032 
 1033 
Figure 9. Decision tree showing how an overall assessment and confidence score could be derived for the “Events 1034 
in rodent lymphocytes” based on the LLNA. The confidence scores here are based on RS1/2 experimental data 1035 
(except in the case of *): assuming relevant data and high reliability, and, in practice, confidence scores may need 1036 
to be adjusted based on reliability scores. *Concentrations tested in the LLNA are either non-irritating or mildly 1037 
irritating. The low confidence score reflects the non-specific increase in lymphocyte proliferation that could occur 1038 
with irritants.    1039 
Figure 10. Decision tree showing how an overall assessment and confidence score could be derived for 1040 
the ‘skin sensitization in rodents’ endpoint based on guinea pig tests. The confidence scores here are 1041 
based on RS1 experimental data (except in the case of *): assuming relevant data and high reliability, 1042 
and, in practice, confidence scores may need to be adjusted based on reliability scores. *GPMT/BT 1043 
37 
 
challenge concentrations are non-irritating; however, deviations from OECD 406 may reduce the 1044 
relevance of the study and decrease the confidence in the endpoint.  1045 
 1046 
Figure 11a. Derivation of the ‘skin sensitization in vitro’ endpoint using the “AOP 2 out of 3” approach 1047 
(Case 1a) 1048 
Figure 11b. Derivation of the ‘Skin Sensitization in Rodents’ endpoint  1049 
Figure 11c. Derivation of the ‘skin Sensitization in Humans’ endpoint from the weight of evidence 1050 
presented from the ‘Skin Sensitization skin in vitro’ and ‘Skin Sensitization in Rodents’ endpoints. DPT 1051 
data is also used to support the overall assessment.  1052 
Figure 12a. Derivation of the ‘skin sensitization in vitro’ endpoint using the “AOP 2 out of 3” approach 1053 
(Case 2) 1054 
Figure 12b. Derivation of the ‘Skin Sensitization in Humans’ using the “AOP 2 out of 3” approach (Case 2) 1055 
 1056 
 1057 
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Tables 
 
Table 1. Sources of data for the development of in silico methods 
Database Description 
NTP-ICE Integrated Chemical Environment (ICE), an open access database with results from NTP 
Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
SkinSensDB SkinSensDB is a collection of data from published literature to facilitate the development of AOP-
based computational prediction methods(Wang et al. 2017) 
ECHA-CHEM European Chemicals Agency (ECHA) database is an open access database containing data for 
chemicals manufactured and imported in Europe. Although the summaries are publicly available, 
extracting data in large amounts requires special consideration as the studies are proprietary 
TOXNET-HSDB Hazardous Substances Data Bank (HSDB) is an open source database that provides information 
on human exposure to potentially hazardous chemicals 
EURL-ECVAM-  
DB-ALM 
The European Union Reference Laboratory for alternatives to animal testing database service on 
alternative methods to animal experimentation is an open access database, containing 
information on percutaneous absorption 
CosIng European Commission database of current and historical data for cosmetic substances and 
ingredients  
RIFM The Research Institute For Fragrance Materials (RIFM) monographs contain human health and 
toxicological data for fragrance and flavor raw materials.  
Proprietary Databases generated within a specific institution. Structure activity relationship (SAR) 
fingerprints 
Literature Manual curation of peer-reviewed articles and published training sets such as (MTD Cronin, 
1994) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 2. Examples of deriving an overall assessment and confidence for the “skin sensitization in vitro” 
endpoint using the “AOP 2 out of 3” approach 
 
Assessment and confidence scores Overall 
Assessment 
Explanation 
  
Covalent Interaction 
with Skin Proteins 
Events in 
Keratinocytes 
Events in 
Dendritic cells 
Skin sensitization  
in vitro 
Positive, high 
confidence 
Positive, high 
confidence 
Negative, low 
confidence 
Positive, high 
confidence 
Positive, high confidence is the 
majority assessment 
Negative, high 
confidence 
Negative, high 
confidence 
Positive, high 
confidence 
Negative, medium 
confidence 
Negative is the majority 
assessment, the confidence 
score is lowered based on a 
consideration of a third high 
confidence result 
Positive, high 
confidence 
Positive, medium 
confidence 
Positive, low 
confidence  
Positive, medium 
confidence 
Positive is the majority 
assessment, the confidence 
score is medium based on 
three aligned calls with 
different confidence scores 
Negative, high 
confidence 
Negative, 
medium 
confidence 
Positive, 
medium 
confidence 
Negative, medium 
confidence 
Negative is the majority 
assessment, the lower 
confidence score of the two 
aligned calls  propagates to the 
overall assessment 
Negative, Low 
confidence 
 Positive, Low 
confidence 
Inconclusive  The assessments are non-
concordant and the confidence 
scores are aligned 
 
 
 
 
  
 
Table 3: Factors increasing and decreasing confidence in a human study (Schulz, Altman, and Moher 
2010; Sibbald and Roland 1998) 
Factors increasing confidence Factors decreasing confidence 
Objective clearly stated and linked to measured 
outcome 
Ambiguous objective, poorly linked to measured 
outcome 
Randomized controlled study 
Randomized double-blind study 
Uncontrolled and not randomized (or case report) 
No blinded control in study 
Study conducted long enough to observe the 
effect 
Study duration too short to observe the effect 
Control substance application matches test 
substance application and represents the real-
world exposure 
Control substance application does not match test 
substance application or does not represents the real-
world exposure scenario 
Outcome clearly defined and measured through 
a quantitative endpoint 
Subjective outcome based on perception 
Statistical rationale behind determination of 
sample size 
No rationale behind sample size selection 
Description of study population available for 
review 
No description of study population available 
 
 
 
 
 
 
 
 
Table 4: Elements of an in silico toxicology report  
 
Section Content 
Title page - Title (including information on the decision context) 
- Who generated the report and from which organization 
- Who performed the in silico analysis and/or expert review, including their organization 
- Date when this analysis was performed 
- Who the analysis was conducted for 
Executive summary - Provide a summary of the study 
- Describe the toxicity or properties being predicted 
- Include a table or summary showing the following: 
o The chemical(s) analyzed  
o Summary of in silico results, reviewed experimental data and overall 
assessment for each toxicological effect or mechanism 
o Summary of toxicological endpoint assessment and confidence 
o Summary of supporting information 
Purpose - Specification of the problem formulation 
Materials and 
methods 
- QSAR model(s), expert alerts, and other models used with version number(s) and any 
parameters set as part of the prediction (e.g., QMRF
1
 format) 
- Databases searched with version number(s) 
- Description of any IATAs, DIPs, DAs used 
- Tools used as part of any read-across with version number(s) 
Results of Analysis - Details of the results and expert review of the in silico models and any experimental data, 
including results of the applicability domain analysis 
- Report of any read-across analysis, including source analogs and read-across justifications 
Conclusion - Summarize the overall analysis including experimental data, in silico methods and expert 
review  
- Final prediction that is based on expert judgment 
References - Complete bibliographic information or links to this information, including test guidelines 
referred to in the experimental data, etc. 
Appendices (optional) - Full (or summary) study reports used or links to the report, detailed (or summary) in silico 
reports, reports on the models used (e.g., QMRF reports) 
1
QMRF – QSAR Model Reporting Format 
 
















 Highlights 
1. Details a hazard assessment framework for skin sensitization that includes experimental data 
and in silico results 
2. Defines rules and principles for deriving an assessment from the available information 
3. Outlines criteria to be considered as part of an expert review of an assessment 
4. A method for assigning confidence to skin sensitization assessments is proposed 
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